Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
14.68
-0.39 (-2.59%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Immunovant Employees
Immunovant had 207 employees as of March 31, 2024. The number of employees increased by 43 or 26.22% compared to the previous year.
Employees
207
Change (1Y)
43
Growth (1Y)
26.22%
Revenue / Employee
n/a
Profits / Employee
-$1,848,841
Market Cap
2.50B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IMVT News
- 5 weeks ago - Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward - Seeking Alpha
- 5 weeks ago - Immunovant's muscle disorder treatment meets main goal in late-stage trial - Reuters
- 5 weeks ago - Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies - GlobeNewsWire
- 5 weeks ago - Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs - GlobeNewsWire
- 2 months ago - Immunovant Reports Financial Results for the Quarter Ended December 31, 2024 - GlobeNewsWire
- 3 months ago - Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm - PRNewsWire
- 4 months ago - Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal Study - Seeking Alpha
- 4 months ago - FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Forecast to 2034 - Immunovant Advances FcRn Inhibitor Pipeline with Promising Results and FDA Green Light for Pivotal Trial - GlobeNewsWire